Inclusion Criteria:

1. Willing and able to give written informed consent.

2. History of uveal melanoma. For the adjuvant arm, eligible patients must have
completed local therapy for the eye no more than 12 months prior to enrollment. For
the metastatic arm, documented metastatic disease with at least one measurable lesion
is required which is >/=1 cm x 1 cm (on spiral CT or equivalent)

3. For the adjuvant arm, patients must be identified as high-risk based on any of the
following: Class 2 gene expression signature using DecisionDx-UM and/or complete
testing, or monosomy 3 and/or apical thickness greater than 8.0-mm. If a patient is
eligible for both Cohort 1 and Cohort 2 based on multiple factors, the patient will
be enrolled on Cohort 1.

4. Any number of prior therapies is allowed.

5. Required values for initial laboratory tests: WBC >/= 2000/uL, ANC >/= 1000/uL,
Platelets >/= 75 x 103/uL, Hemoglobin >/= 9 g/dL, Creatinine AST/ALT metastases, Bilirubin must have a total bilirubin less than 3.0 mg/dL)

6. No active or chronic infection with HIV, Hepatitis B, or Hepatitis C.

7. Performance status ECOG 0-1.

8. Men and women, >/= 18 years of age. Because no dosing or adverse event data are
currently available on the use of ipilimumab in patients are excluded from this study.

9. Baseline imaging in the form of CT chest, abdomen, pelvis with oral and intravenous
contrast within 28 days of study entry. For patients with a contrast allergy, choice
of alternative body imaging will be at the discretion of the investigator or his
designee. MRI of the brain is only needed if clinically indicated.

10. Prior to start of treatment must be more than 21 days elapsed from surgery, radiation
therapy, or prior chemotherapy. More than 42 days elapsed from prior immune therapy
including vaccines.

11. Women of childbearing potential (WOCBP) and fertile men with partners of childbearing
potential must be using an adequate method of contraception to avoid pregnancy
throughout the study and for up to 26 weeks after the last dose of investigational
product, in such a manner that the risk of pregnancy is minimized.

Exclusion Criteria:

1. Untreated primary uveal melanoma except in cases where metastatic disease is
diagnosed at the time of primary disease.

2. Metastatic uveal melanoma patients with bone-only disease.

3. Any other malignancy from which the patient has been disease-free for less than 2
years, with the exception of adequately treated and cured basal or squamous cell skin
cancer, superficial bladder cancer or carcinoma in situ of the cervix, breast, or
prostate.

4. Autoimmune disease: Patients with a history of inflammatory bowel disease, including
ulcerative colitis and Crohn's Disease, are excluded from this study, as are patients
with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic
progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune
vasculitis [e.g., Wegener's Granulomatosis]); motor neuropathy considered of
autoimmune origin (e.g. Guillain-Barre Syndrome and Myasthenia Gravis).

5. Any underlying medical or psychiatric condition, which in the opinion of the
investigator will make the administration of ipilimumab hazardous or obscure the
interpretation of AEs, such as a condition associated with frequent diarrhea.

6. Any non-oncology vaccine therapy used for prevention of infectious diseases (for up
to 1 month before or after any dose of ipilimumab).

7. A history of prior treatment with ipilimumab or prior CD137 agonist or CTLA 4
inhibitor or agonist.

8. Concomitant therapy with any of the following: tamoxifen, toremifene, IL 2,
interferon, or other non-study immunotherapy regimens; cytotoxic chemotherapy;
immunosuppressive agents; other investigation therapies; or chronic use of systemic
corticosteroids. Ocular steroid use is acceptable.

9. Women of childbearing potential (WOCBP)who: (a.) are unwilling or unable to use an
acceptable method of contraception to avoid pregnancy for their entire study period
and for up to 26 weeks after cessation of study drug, or (b.) have a positive
pregnancy test at baseline, or (c.) are pregnant or breastfeeding.

10. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for
treatment of either a psychiatric or physical (e.g., infectious) illness.